Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L. Hertz, Howard L. McLeod, Kouros Owzar et al.|Clinical Cancer Research|2016Cited by 57
Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinionSusanna B. Park, Ahmet Höke, Susan G. Dorsey et al.|Expert Review of Neurotherapeutics|2021Cited by 25
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyMichael J. Kelley, Daniel L. Hertz, Yusuke Nakamura et al.|Loyola eCommons (Loyola University of Chicago)|2020Cited by 4
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)Jai N. Patel, Howard L. McLeod, Chen Jiang et al.|The Pharmacogenomics Journal|2024Cited by 1